Tag: Crohn’s Disease
MRI Index Can Predict Postop Recurrence in Crohn Disease
In validation cohort, MONITOR index ≥1 had sensitivity of 87 percent, specificity of 75 percent, NPV of 75 percent
FDA Approves Skyrizi for Moderately to Severely Active Crohn Disease
Skyrizi is first specific interleukin-23 approved to treat Crohn disease
Obesity Linked to Increased Risk for Crohn Disease
Obesity, as measured by BMI, linked to increased risk for CD, but no association seen for ulcerative colitis
Certain Dietary Patterns May Raise Risk for Developing IBD
Carnivorous pattern linked to increased risk for ulcerative colitis; Western dietary pattern linked to increased risk for Crohn disease
Prevalence of Primary Sclerosing Cholangitis in IBD Explored
Prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease is about 2 percent
Intestinal Ultrasound Informs Management of IBD
In 60 percent of patients, IUS had impact on disease management, with change in medication in 47.8 percent
FDA Approves First Interchangeable Biosimilar for Inflammatory Diseases
Cyltezo is first interchangeable monoclonal antibody for RA, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, chronic plaque psoriasis
Prevalence of Primary Sclerosing Cholangitis in IBD Examined
Global prevalence of primary sclerosing cholangitis ranges from 0.96 percent in Crohn disease to 2.47 percent in ulcerative colitis
Outcome Measure Developed for Crohn’s Perianal Fistula
Crohn's Anal Fistula QoL has good internal consistency, excellent stability, good responsiveness and construct validity
Diets Compared for Mild-to-Moderate Crohn Disease in Adults
Rate of symptomatic remission at week 6 similar for Mediterranean diet, specific carbohydrate diet in randomized trial
